Jianxuan Zou

Activating<i>KRAS</i>,<i>NRAS</i>, and<i>BRAF</i>mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma

Fazal Shirazi, Richard J. Jones, Ramesh Singh et al. · Proceedings of the National Academy of Sciences · 2020 · 77 citations · Full text

Immunotherapy based on bispecific T‐cell engager with <scp>hIgG</scp>1 Fc sequence as a new therapeutic strategy in multiple myeloma

Jianxuan Zou, Dan Chen, Yunhui Zong et al. · Cancer Science · 2015 · 48 citations · Full text

Hematological Malignancy, Cancer Immunosurveillance, Fc Sequence +13

La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease

Huimin Meng, Xue Sun, Yanhui Song et al. · Clinical Immunology · 2018 · 36 citations

Autoimmune Disease, Autoantibody Production, Immunology +9

Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization

Dan Chen, Jianxuan Zou, Yunhui Zong et al. · Immunopharmacology and Immunotoxicology · 2016 · 30 citations

Immunology, Immunotherapy, Tumor Biology +17

The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance

Jianxuan Zou, Richard J. Jones, Hua Wang et al. · Journal of Molecular Medicine · 2020 · 13 citations · Full text

Hematological Malignancy, Lenalidomide Resistance, Novel Therapy +6